Ataxia telangiectasia and Rad3 related

Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, BAY, Alzheimer's disease, AstraZeneca, Cholangiocarcinoma, Genetic testing, Ovarian cancer, Therapy, Parkinson's disease, Breast, Emotional dysregulation, Research, Virus, Clinical trial, Berzosertib, COVID-19, Viral, Ataxia telangiectasia and Rad3 related, Radiation, HIV-1, DNA repair, Vertex Pharmaceuticals, Bone marrow, Cancer, Investment, ATR, Patient, Ataxia–telangiectasia, DNA, Pharmaceutical industry, Vaccine, Bayer, Merck

A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Key Points: 
  • A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.
  • Pipeline Analysis: The report offers insights into the global ATR protein inhibitors clinical pipeline, categorized by company, indication, and phase.
  • Development Trends: ATR inhibitors are expanding their scope to include neurodegenerative diseases and viral infections, opening new avenues for treatment.
  • This innovative approach to targeting DNA damage response pathways has the potential to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Biomarker, AACR, Ataxia telangiectasia and Rad3 related, Mouse, Patient, Hong Kong Stock Exchange, Company, IND, Antibody, DDR, SHP2, Survival, IMAB362, Annual report, Immunosuppression, Cancer, Mutation, Date, MUC5B, NDA, Homologous recombination, Lung cancer, AM, KRAS, Tumor microenvironment, SEHK, CDX, Adenosine, Metabolism, DNA, Border, Risk, Greater, Stomach, CD73, MTOR, American Association, NDAS, 2021 Essex County Council election, Ataxia–telangiectasia, II, ATR, Drug discovery, XPO1, Compugen (Israeli company), Time, PDX, Association, Program, AMP, Vaccine, Pharmaceutical industry, Flour

CD73 is an enzyme that is highly expressed in the tumor microenvironment and enables the degradation of AMP into adenosine, resulting in immunosuppression and cancer progression.

Key Points: 
  • CD73 is an enzyme that is highly expressed in the tumor microenvironment and enables the degradation of AMP into adenosine, resulting in immunosuppression and cancer progression.
  • In vitroassays were used to assess each compound's ability to inhibit CD73 function and reverse AMP/adenosine mediated T-cell suppression.
  • Compared to the two antibodies, ATG-037 demonstrated more potent and complete inhibitory activity of cell surface CD73 in this study.
  • Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases.

EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

Retrieved on: 
Monday, April 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Berzosertib, Ovarian cancer, Clinical medicine, Gemcitabine, Health, Ataxia telangiectasia and Rad3 related, Medicine

Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type,3 and it is the lead candidate in EMD Serono\xe2\x80\x99s DNA Damage Response (DDR) inhibitor portfolio.

Key Points: 
  • Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type,3 and it is the lead candidate in EMD Serono\xe2\x80\x99s DNA Damage Response (DDR) inhibitor portfolio.
  • Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
  • Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
  • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.

McAfee Advanced Threat Research and JSOF Collaborate to Defend Against Exploitation of Ripple20 Vulnerabilities

Retrieved on: 
Wednesday, August 5, 2020
Software, Networks, Internet, Hardware, Data management, Technology, Mobile, Wireless, Security, Computer security, Cyberwarfare, Computer network security, Antivirus software, John McAfee, McAfee, Computing, Ataxia telangiectasia and Rad3 related, Vulnerability, McAfee, McAfee Advanced Threat Research, JSOF

BLACK HAT USA--McAfee Advanced Threat Research (ATR), a leading source for threat research, threat intelligence, and cybersecurity thought leadership, today announced a joint research effort with JSOF, who discovered and responsibly disclosed 19 zero-day vulnerabilities known by the name of Ripple20.

Key Points: 
  • BLACK HAT USA--McAfee Advanced Threat Research (ATR), a leading source for threat research, threat intelligence, and cybersecurity thought leadership, today announced a joint research effort with JSOF, who discovered and responsibly disclosed 19 zero-day vulnerabilities known by the name of Ripple20.
  • Through this research collaboration, McAfee ATR has produced signatures and the industrys first comprehensive detection logic, designed for network administrators and security personnel looking to further understand these vulnerabilities and defend against exploitation.
  • At McAfee Advanced Threat Research we often advocate for collaboration; with this research effort weve highlighted just how effective it can be when we work together, said Steve Povolny, head of McAfee ATR.
  • www.mcafee.com
    McAfee Advanced Threat Research is a leading source for threat research, threat intelligence, and cybersecurity thought leadership.

Serine Threonine Protein Kinase ATR, Pipeline Review, H2 2019 - Artios Pharma Ltd, Bayer AG, IMPACT Therapeutics Inc & Pfizer Inc - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Health, Pharmaceutical, Proteins, Branches of biology, Ataxia telangiectasia and Rad3 related, ATR, Biology, Phosphatidylinositol 3-kinase-related kinase, SNRK

The "Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Serine Threonine Protein Kinase ATR - Pipeline Review, H2 2019'; Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules.
  • Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene.
  • It also reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

Retrieved on: 
Wednesday, November 6, 2019
University of Texas MD Anderson Cancer Center, University of Texas System, Ataxia telangiectasia and Rad3 related, Monroe Dunaway Anderson, Cancer, Health, Causes of death

CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announcethe in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.

Key Points: 
  • CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announcethe in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
  • "This programme has the potential to be a highly effective DNA damage response (DDR) targeted treatment in cancer.
  • We look forward to advancing the work done by MD Anderson and ShangPharma for the benefit of cancer patients," said Dr. Niall Martin, Chief Executive Officer at Artios Pharma.
  • The ATR inhibitor programme is the result of an extensive collaboration between MD Anderson's Therapeutics Discovery team and ShangPharma.

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

Retrieved on: 
Wednesday, November 6, 2019
University of Texas MD Anderson Cancer Center, University of Texas System, Ataxia telangiectasia and Rad3 related, Monroe Dunaway Anderson, Cancer, Health, Causes of death

CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announcethe in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.

Key Points: 
  • CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announcethe in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
  • "This programme has the potential to be a highly effective DNA damage response (DDR) targeted treatment in cancer.
  • We look forward to advancing the work done by MD Anderson and ShangPharma for the benefit of cancer patients," said Dr. Niall Martin, Chief Executive Officer at Artios Pharma.
  • The ATR inhibitor programme is the result of an extensive collaboration between MD Anderson's Therapeutics Discovery team and ShangPharma.

WILL Interactive and Crisis Consultant Group Create Potentially Life-Saving Response to Workplace Violence

Retrieved on: 
Wednesday, March 13, 2019
Distance education, Workplace, Ataxia telangiectasia and Rad3 related, Educational technology, Articles, Technology

WASHINGTON, March 13, 2019 /PRNewswire/ -- To address an urgent and growing need, WILL Interactive and Crisis Consultant Group have created"Active Threat Response: What Everyone Should Know" (ATR).

Key Points: 
  • WASHINGTON, March 13, 2019 /PRNewswire/ -- To address an urgent and growing need, WILL Interactive and Crisis Consultant Group have created"Active Threat Response: What Everyone Should Know" (ATR).
  • This groundbreaking interactive video training brings CCG's proven curriculum to life online using WILL's evidence and scenario-based learning.
  • ATR uses gaming, storytelling, and interactive movie to create a highly engaging and memorable learning experience in which users become the characters in a workplace active threat situation.
  • According to the Bureau of Labor Statistics, workplace homicides averaged 435 annually in the most recent five-year period surveyed, and co-workers were responsible for a large percentage of workplace violence.

Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Retrieved on: 
Thursday, January 24, 2019
Merck, Merck Group, Ataxia telangiectasia and Rad3 related, Darmstadt, Healthcare industry, Health, Companies

Both molecules were acquired in a licensing agreement from Vertex in 2017, and are part of the company's broad portfolio of DNA Damage Response (DDR) inhibitors.

Key Points: 
  • Both molecules were acquired in a licensing agreement from Vertex in 2017, and are part of the company's broad portfolio of DNA Damage Response (DDR) inhibitors.
  • "This transaction illustrates our determination to maximize value creation from our pipeline," said Beln Garijo, Member of the Executive Board and CEO Healthcare, Merck KGaA, Darmstadt, Germany.
  • The company is currently investigating four DDR molecules, including two ATR inhibitors, an ATM inhibitor and an investigational small-molecule of DNA-PK.
  • Merck KGaA, Darmstadt, Germany, a vibrant science and technology company, operates across healthcare, life science and performance materials.

Andrea Brenholz Promoted to CEO/President of ATR International

Retrieved on: 
Monday, October 8, 2018
France–Italy relations, ATR, Toulouse, Ataxia telangiectasia and Rad3 related, Transport, Aviation

SUNNYVALE, Calif., Oct. 8, 2018 /PRNewswire-PRWeb/ -- ATR International, a leading staffing and consulting firm specializing in IT and engineering, has announced the promotion of Andrea Brenholz to the role of CEO/President.

Key Points: 
  • SUNNYVALE, Calif., Oct. 8, 2018 /PRNewswire-PRWeb/ -- ATR International, a leading staffing and consulting firm specializing in IT and engineering, has announced the promotion of Andrea Brenholz to the role of CEO/President.
  • "It's an honor to be named the head of such a respected industry leading organization," said Andrea Brenholz, CEO/President of ATR International.
  • "Passing the torch to Andrea is a source of great pride for me," commented Jerry Brenholz, Co-Founder of ATR International.
  • "There is no one better prepared than Andrea to carry on the legacy of ATR into the future," stated Maria Novoa-Brenholz, Co-Founder/Principal of ATR International.